AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06468787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kosmos Anatomical Object Labeling and View Identification Algorithms
Description: Participants underwent limited ultrasound scanning by both cardiac sonographers and abdominal sonographers. Algorithm's performance on the view identification task and the object labeling task is compared to majority opinion of 5 radiologists.
Study NCT06367595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: IV magnesium sulfate versus magnesium sulfate to intrathecal hyperbaric bupivacaine
Study NCT06367595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium sulfate
Description: IV magnesium sulfate versus magnesium sulfate to intrathecal hyperbaric bupivacaine
Study NCT05640180 — intervention group
Intervention type: DRUG
Intervention: Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
Description: Retrospective cohort analysis using United States Optum Electronic Health Records data.
Study NCT05936177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient education
Description: The intervention in this osteoporosis education research will consist of a concise and informative educational session delivered by a physiatrist, utilizing slides prepared based on information from reputable sources such as the International Osteoporosis Foundation website and the World Health Organization (WHO) health education booklet. The session will cover various topics including the definition of osteoporosis, its causes, risks, complications, dietary options, and specific exercise recommendations, with a focus on raising awareness and promoting informed decision-making regarding prevention and treatment options.
Study NCT05249686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy + Dry Needling
Description: Dry Needling: This is a minimally invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle in order to stimulate myofascial trigger points (MTrP) provoking one to six local twitch responses (LTR).~Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ).
Study NCT05249686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ).
Study NCT05670327 — intervention group
Intervention type: OTHER
Intervention: Diaphragmatic ultrasound assessment
Description: TFdi, diaphragmatic dysplacement, NAVA assessment, respiratory paramenters
Study NCT05231317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: 16 days with all foods provided
Study NCT05231317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western diet
Description: 16 days with all foods provided
Study NCT05843461 — intervention group
Intervention type: OTHER
Intervention: Pulmonary Index of Microcirculatory Resistance
Description: PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery. PIMR of the right and left pulmonary arteries will be obtained.
Study NCT05843461 — intervention group
Intervention type: OTHER
Intervention: Right Ventricle Index of Microcirculatory Resistance
Description: RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.
Study NCT05843461 — intervention group
Intervention type: OTHER
Intervention: Pulmonary artery OCT
Description: OCT of the pulmonary artery involves advancing an OCT catheter over the pressure wire to image the pulmonary artery. OCT of the right and left pulmonary arteries will be performed.
Study NCT04898478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Seeking Intervention for Pacific Islanders with Opioid Use Disorders
Description: The investigators will design a culturally grounded treatment seeking intervention for Pacific Islanders with OUDs
Study NCT05164315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tailored surgery
Description: Procedure: Tailored surgery based on intraoperative local excision/biopsy
Study NCT05164315 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total mesorectal excision (TME)
Description: Procedure: Total mesorectal excision for all allocated patients
Study NCT05253404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu® AuraOnce™ Disposable Laryngeal Mask
Description: Switching endotracheal tube to laryngeal mask at sevoflurane 2.63-2.97%, Removing endotracheal tube when spontaneously generating tidal volume of >4ml/kg, EtCO2\<45mmHg, Train of four ratio >70-90%.
Study NCT06543485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intramedullary screw fixation of metacarpal fractures
Description: intramedullary screw fixation of metacarpal fractures through limited open approach
Study NCT04781816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443122
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study NCT04781816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study NCT05930080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKCPT
Description: the randomly assigned subjects took the study drug for 12 weeks
Study NCT05930080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex
Description: the randomly assigned subjects took the study drug for 12 weeks
Study NCT05528575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry, cranberry, green tea extract, cocoa
Description: tablet supplements, available readily.
Study NCT05528575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GOS, Inulin, RS2
Description: Prebiotic combination, Inulin, GOS and RS2
Study NCT05528575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: prebiotics and polyphenols
Description: combination of the same prebiotics and polyphenols as above
Study NCT05528575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: maltodextrin, 10g per day
Study NCT05613842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper-64 labelled SAR-Bombesin
Description: radiolabeled antagonist analog of bombesin for the diagnosis and treatment of gastrin releasing peptide receptor (GRPR)-positive tumors in adults. The product is Copper-64 labelled SAR-Bombesin (Cu-SAR-BBN). Cu-SAR-BBN uses radioactive forms (radionuclide) of copper, copper-64 (64Cu) to image cancers using Positron Emission Tomography (PET) and then copper-67 (67Cu) for therapy by internal beta radiation. 64Cu-SAR-BBN has 3 basic components; the radionuclide (64Cu), bound via MeCOSar (a bifunctional metal chelator, SAR) to a bombesin analog that targets GRPR.
Study NCT05501288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huashi Baidu granule
Description: Patients were given HSBDG the day after randomization, with a dose of 2.5g for age 3 to 6 years, 5 g for age 7 to 12 years, and 10 g for age 13 to 18 years, twice daily for 5 consecutive days.
Study NCT05501288 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: compound pholcodine oral solution
Description: Patients were given compound pholcodine oral solution (Bright Future Pharmaceuticals Factory, Hong Kong, CHN) the day after randomization, with a dose of 5 ml for age 3 to 6 years and 10 ml for age 7 to 18 years, three times daily for 5 consecutive days.
Study NCT05948852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: metabolic surgery (SADIS and OAGB)
Description: TWO HYPOABSORPTION TECHNIQUES FOR THE TREATMENT OF TYPE III OBESITY (BODY MASS INDEX BETWEEN 45 - 49.9 KG/M2): SINGLE ANASTOMOSE DUODENAL SWITCH (SADI-S) AND SINGLE ANASTOMOSE GASTRIC BY-PASS (OAGBP).
Study NCT05948852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: metabolic surgery (SADIS and OAGB)
Description: TWO HYPOABSORPTION TECHNIQUES FOR THE TREATMENT OF TYPE III OBESITY (BODY MASS INDEX BETWEEN 45 - 49.9 KG/M2): SINGLE ANASTOMOSE DUODENAL SWITCH (SADI-S) AND SINGLE ANASTOMOSE GASTRIC BY-PASS (OAGBP).
Study NCT04819113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: MenACWY-TT vaccine
Study NCT06509711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLYOMETRICS jump training with HIIT (4 weeks,3 sessions per week)
Description: First set of drills 6 x 40-cm hurdle jumps +5-s sprint\* at 130% of aerobic maximum speed. Second set of drills 6 x 30-cm hurdle jumps with extended legs + 5-s sprint at 130% of aerobic maximum speed. Third set of drills 6 x horizontal jumps + 5-s sprint at 130% of aerobic maximum speed. Fourth set of drills 3 right-leg and 3left-leg hops +5-s sprint at 130% of aerobic maximum speed. Each drills set was performed 2 times in a row. Afterwards, 10 seconds of rest were allowed. Thereafter, this sequence of effort-rest was repeated 8 times. After then, a 3-5 min recovery period was allowed before commencing the next drills set;
Study NCT06509711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLYOMETRICS JUMP TRAINING WITHOUT HIIT (4weeks, 3sessions Per week)
Description: Plate pogo (4 reps, 3 sets) Broad jump( 4reps,3 sets)
Study NCT05397483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Legal Education plus Trauma-informed Therapy (LETiT)
Description: Group-1: Experimental (n=75 participants) will receive the LETiT which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
Study NCT05397483 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention As Usual (IAU)
Description: Group-2: Controlled (n=75 participants) will receive the IAU which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
Study NCT05563168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DILTIAZEM TEVA 60 mg or placebo
Description: DILTIAZEM TEVA 60 mg 3 times a day during 7 days + standard of care Or placebo 3 times a day during 7 days + standard of care.
Study NCT05563168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DILTIAZEM TEVA 60 mg or placebo
Description: DILTIAZEM TEVA 60 mg 3 times a day during 7 days + standard of care Or placebo 3 times a day during 7 days + standard of care.
Study NCT05570032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Description: In intervention the participants took part in the VR training. The X-BOX 360 (Augmented virtual reality) device was used. The participants were guided about the virtual reality training including Kinect sports gamming (Trail 1. badminton, beach volley ball, Soccer goal keeping). Each training was performed for 15 minutes with 5 minutes break time. The whole training was performed for 8 weeks. After eight weeks final assessment was done through outcome measuring tools (TUG test, MAS scale, forward stepping test and Functional reach test).
Study NCT05454280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensified post-discharge surveillance
Description: * TCC Nurse Televisit at post-discharge day 1 and 7~* Televisit with APP/Resident/Fellow between post-discharge day 3-5~* Referral for home health nursing evaluation upon discharge
Study NCT05454280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard post-discharge surveillance
Description: Patients in the Control Arm will receive standard post-discharge surveillance, as deemed appropriate/necessary by the surgeons caring for them at the time of hospital discharge.
Study NCT06648486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With the assistance of wearable isokinetic training robot
Description: A child with SMA will use a wearable isokinetic training robot to train the knee joint for 20 sessions.
Study NCT06356168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Virtual Reality
Description: Participants interact using virtual reality during dialysis.
Study NCT06356168 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Virtual Reality
Description: Participants use virtual reality alone during dialysis.
Study NCT04870151 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterolateral approach
Description: Cemented hemiarthroplasty using an anterolateral approach.
Study NCT04870151 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct lateral approach
Description: Cemented hemiarthroplasty using a direct lateral approach.
Study NCT05788601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapiglutide
Description: GLP-1/GLP-2 receptor agonism
Study NCT05788601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05004662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered automated treatment
Description: An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
Study NCT05004662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Participants will be provided with a 10-week supply of nicotine patches
Study NCT05004662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Participants will be provided with a 10-week supply of nicotine patches
Study NCT05004662 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counceling
Description: Phone counseling with the Florida Quitline
Study NCT05004662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Participants will be provided with a 10-week supply of nicotine lozenges
Study NCT05004662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine lozenge
Description: Participants will be provided with a 10-week supply of nicotine lozenges
Study NCT04736472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic test
Description: Patients with reduced function alleles (DPYD intermediate or poor metabolizer and/or UGT1A1 poor metabolizer) will be recommended to receive dose reductions per clinical pharmacogenetic guidelines. Patients that do not carry actionable alleles (DPYD normal metabolizer and/or UGT1A1 normal or intermediate metabolizer) will receive standard dosing.
Study NCT05914194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NLS-2
Description: Participants will receive NLS-2 tablets orally.
Study NCT05914194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive NLS-2 matching placebo tablets orally.
Study NCT06544408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cool B70 AP Coil - Active (dl-PFC)
Description: One side of the coil is the active and the other is sham. The B70 AP coil will be positioned over the left dorsolateral prefrontal cortex (dl-PFC).
Study NCT06544408 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cool B70 AP Coil- Sham (dl-PFC)
Description: One side of the coil is the active and the other is sham. The B70 AP coil will be positioned over the left dorsolateral prefrontal cortex (dl-PFC).
Study NCT06544408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cool D-B80 AP Coil - Active (dm-PFC)
Description: One side of the coil is the active and the other is sham. The cool D-B80 AP coil will be positioned over the midline (bilateral) dorsal medial prefrontal cortex (dmPFC) using location 25.8% distance from nasion to inion.
Study NCT06544408 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cool D-B80 AP Coil - Sham (dm-PFC)
Description: One side of the coil is the active and the other is sham. The cool D-B80 AP coil will be positioned over the midline (bilateral) dorsal medial prefrontal cortex (dmPFC) using location 25.8% distance from nasion to inion.
Study NCT06544408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cool B70 Treatment Coil - Active Only
Description: The treatment will be the same as the left dl-PFC accel-TMS dl-PFC except that the Cool B70 Treatment coil only has an active treatment coil.
Study NCT06504940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib combined with bendamustine and rituximab
Description: they will receive three cycles of Orelabrutinib combined with bendamustine and rituximab (BR: bendamustine 70mg/m\^2 on days 1-2; rituximab 375mg/m\^2 on day 0). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 21 cycles, each cycle 28 days).
Study NCT06504940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib combined with obinutuzumab
Description: they will receive six cycles of Orelabrutinib combined with obinutuzumab (G 1000mg iv on days 1, 8, 15 of cycle 1, and day 1 of cycles 2-6; Orelabrutinib 150mg once daily). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 18 cycles, each cycle 28 days ).
Study NCT05552118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cochlear™ Remote care
Description: Cochlear™ Remote Check is a virtual assessment tool which helps the clinician to monitor the participant hearing progress remotely. It allows the participant to complete a series of hearing tests using the Cochlear™ Nucleus® Smart App then electronically send the results to the clinician for review.~Cochlear™ Remote Assist enables a video call appointment through the Cochlear™ Custom Sound® Pro software and the Nucleus® Smart App. When remote check requires further follow-up, it allows the clinician to make programming adjustments and sound processor settings without a clinic visit.
Study NCT05552118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Routine in clinic face-to-face care and sound processor programming using Cochlear™ Custom Sound® Pro
Study NCT05552118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant CI600 Series, CI500 Series or Freedom Series and Sound processor Nucleus 7 or Kanso 2 (or latest compatible Sound Processor)
Description: CI600 Series (CI612, CI622, CI632), CI500 Series (CI512, CI522, CI532), Freedom Series (CI24RE(CA), CI24RE(ST), CI422). Nucleus 7 (CP1000) or Kanso 2 (CP1050)
Study NCT05552118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear Implant CI600 Series, CI500 Series or Freedom Series and Sound processor Nucleus 7 or Kanso 2 (or latest compatible Sound Processor)
Description: CI600 Series (CI612, CI622, CI632), CI500 Series (CI512, CI522, CI532), Freedom Series (CI24RE(CA), CI24RE(ST), CI422). Nucleus 7 (CP1000) or Kanso 2 (CP1050)
Study NCT06381336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRAK-SILVER platform
Description: The Experimental Group used TRAK-SILVER, a cross-platform web application that empowers healthcare professionals and patients. It facilitates the management of a patient's condition by providing therapeutic exercises, monitoring activity, and administering clinical assessment scales and questionnaires. The platform's advanced artificial vision algorithm, known for its precision, enhances patient engagement with real-time measurements and corrections during exercise.~Physiotherapists monitored the sessions through the TRAK-SILVER platform's monitoring system and weekly phone calls. The TRAK-SILVER platform had an alert notification system.~The program's second part involved weekly uploads of health-promoting information pills to the platform.
Study NCT05753215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline Pill
Description: Omadacycline will be administered 300 mg orally daily without the loading dose.
Study NCT05753215 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care
Description: Prior to randomization, SOC antibacterial therapy will be selected by the subject's treating physician.
Study NCT05203666 — intervention group
Intervention type: OTHER
Intervention: percutaneous removable interspinous process
Description: percutaneous removable interspinous process spacer a neurologic intermittent clauditation due to a degenerative lumbar spinal stenosis.
Study NCT05568693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.3ml of mRNA vaccine
Description: Subjects received 0.3ml of mRNA vaccine intramuscularly
Study NCT06263062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awareness-Based Coping with Fear of Cancer Programme
Description: The content of the Training Program was created by researchers based on MBSR, in line with high-level research results and international guides.Then, the necessary arrangements were made bytaking the opinions of 10 experts ( faculty members of the department of obstetrics and gynaecology nursing, psychiatry specialist, faculty members of the gynaecology oncology department, oncology clinic psychologist, obstetrics and gynaecology clinic charge nurse). Content concluded in accordance with the comments received.
Study NCT04817566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA).
Study NCT04817566 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants.